Ascorbic acid: Useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals

Bioconjugate Chemistry

Volumn 14, Issue 5, 2003, Pages 1052-1056

  Liu, Shuang ^a   Ellars, Charlie E ^b   Edwards, D Scott ^b  

^a PURDUE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BIOMOLECULES; RADIATION CHEMISTRY; RADIOLYSIS; TITRATION;

AMMONIUM ACETATE; BUFFER AGENTS; BUFFER CAPACITY; GOOD'S BUFFERS; INTEGRINS; NONPEPTIDE; PH CONTROL; RADIOLABELLING; RECEPTOR ANTAGONISTS; STABILISER;

STABILIZATION;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMMONIUM ACETATE; ASCORBIC ACID; BUFFER; GENTISIC ACID; INDIUM 111; INTEGRIN RECEPTOR; LUTETIUM; LUTETIUM 177; METAL DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RECEPTOR BLOCKING AGENT; STABILIZING AGENT; TA 138; UNCLASSIFIED DRUG; YTTRIUM 90;

ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL REACTION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONJUGATE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; ISOTOPE LABELING; MOLECULAR SIZE; PH; RADIOLYSIS; REACTION ANALYSIS; TECHNIQUE; TITRIMETRY;

EID: 0141792922     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034109i     Document Type: Article

References (37)

1. Anderson, C. J., and Welch, M. J. (1999) Radiolabeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 99, 2219-2234.
2. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
3. Jurisson, S., and Lydon, J. D. (1999) Potential technetium small molecule radiopharmaceuticals. Chem. Rev. 99, 2205-2218.
4. Volkert, W. A., and Hoffman, T. J. (1999) Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269-2292.
5. Heppeler, H., Froidevaux, S., Eberle, A. N., and Maecke, H. R. (2000) Receptor targeting for tumor localization and therapy with radiopeptides. Current Pharmaceutical Design 6, 971-994.
6. Boerman, O. C., Oyen, W. J. G., and Corstens, F. H. M. (2000) Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 30, 195-208.
7. Heppeler, H., Froidevaux, S., Eberle, A. N., and Maecke, H. R. (2000) Receptor targeting for tumor localization and therapy with radiopeptides. Curr. Pharm. Des. 6, 971-994.
8. Kwekkeboom, D., Krenning, E. P., and de Jong, M. (2000) Peptide receptor imaging and therapy. J. Nucl. Med. 41, 1704-1713.
9. Signore, A., Annovazzi, A., Chianelli, M., Coretti, F., Van de Wiele, C., Watherhouse, R. N., and Scopinaro, F. (2001) Peptide radiopharmaceuticals for diagnosis and therapy. Eur. J. Nucl. Med. 28, 1555-1565.
10. Hoffman, T. J., Quinn, T. P., and Volkert, W. A. (2001) Radiometalated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl. Med. Biol. 28, 527-539.
11. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for target specific therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34.
12. Breeman, W. A. P., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W. H., Kooij, P. P. M., Visser, T. J., and Krenning, E. P. (2001) Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. Eur. J. Nucl. Med. 28, 1421-1429.
13. Liu, S., and Edwards, D. S. (2002) Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Topics in Current Chem. 222, 259-278.
14. Jong, M., Kwekkeboom, D., Valkema, R., and Krenning, E. P. (2003) Radiolabeled Peptides for tumor therapy: current status and future directions. Eur. J. Nucl. Med. 30, 463-469.
15. Fichna, J., and Janecka, A. (2003) Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjugate Chem. 14, 3-17.
16. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5, 565-576.
17. Stimmel, J. B., Stockstill, M. E., and Kull, F. C., Jr. (1995) Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconjugate Chem. 6, 219-225.
18. Kulis, D. L., DeNardo, S. J., DeNardo, G. L., O'Donnell, R. T., and Meares, C. F. (1998) Optimized conditions for chelation of yittrium-90-DOTA immunoconjugates. J. Nucl. Med. 39, 2105-2110.
19. Lewis, M. R., and Shively, J. E. (1998) Maleimidocycteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem. 9, 72-86.
20. Stimmel, J. B., and Kull, F. C., Jr. (1998) Sammarium-153 and lutetium-177 chelation properties of selected macrocyclic and cyclic ligands. Nucl. Med. Biol. 25, 117-125.
21. 90Y-labeled DTPA-biomolecule conjugates. Bioconjugate Chem. 12, 84-91.
22. 111In labeled DTPA-peptide conjugates. Bioconjugate Chem. 12, 630-634.
23. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist for tumor therapy. Bioconjugate Chem. 12, 559-568.
24. 90Y-labeled DOTA-biomolecule conjugates using gentisic and ascorbic acid. Bioconjugate Chem. 12, 554-558.
25. 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. Bioconjugate Chem., in press.
26. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
27. Mousa, S. A. (1998) Mechanism of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future 23, 51-60.
28. Mousa, S. A. (2000) Integrins as novel drug discovery targets: potential therapeutic and diagnostic implications. Emerg. Ther. Targets 4, 143-153.
29. Carmeliet, P. (2000) Mechanism of angiogenesis and atherogenesis. Nat. Med. 6, 389-395.
30. Zitzmann, S., Ethemann, V., and Schwab, M. (2000) Arginine-Glycine-Aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res. 62, 5139-5143.
31. 3 antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 631-645.
32. Garrison, W. M. (1987) Reaction mechanisms in radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 87, 381-398.
33. 99mTc-radiopharmaceuticals. Int. J. Appl. Radiat. Isot. 33, 1341-1344.
34. Chakrabarti, M. C., Le, N., Paik, C. H., De Graff, W. G., and Carrasquillo, J. A. (1996) Prevention of radiolysis of monoclonal antibody during labeling. J. Nucl. Med. 37, 1384-1388.
35. Salako, Q. A., O'Donnell, R. T., and DeNardo, S. J. (1998) Effects of radiolysis on yttrium-90-labeled lym-1 antibody preparations. J. Nucl. Med. 39, 667-670.
36. Kulis, D. L., DeNardo, S. J., DeNardo, G. L., O'Donnell, R. T., and Meares, C. F. (1998) Optimized conditions for chelation of yittrium-90-DOTA immunoconjugates. J. Nucl. Med. 39, 2105-2110.
37. Knapp, F. F., Jr. (Russ), Beets, A. L., Guhlke, S., Zamora, P. O., Bender, H., Palmedo, H., and Biersack, H.-J. (1997) Availability of rhenium-188 from the alumina-based tunsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 17, 1783-1796.